Eden: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Eden's website, https://www.tryeden.com, FDA Establishment Identifier (FEI) 3044020039, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website identify “Eden” on the pictured label, suggesting Eden is the compounder of those drugs when in fact it is not.”

2. 2

   “2. Your website claims that the compounded drug products it offers are sourced from “FDA-licensed 503(a) outsourcing facilities.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&C Act does not establish an "FDA-approved" or "FDA-licensed” designation for pharmacies or outsourcing facilities. Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.”

3. 3

   “While an entity may elect to register with FDA as an outsourcing facility under section 503B of the FD&C Act [21 U.S.C. § 353b], this registration does not constitute FDA approval or licensure of the facility or its compounded drug products.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

tryeden.com returned a live storefront when we checked in August 2026, advertising compounded semaglutide at a published monthly price plus a membership fee, alongside branded Ozempic, Zepbound, Wegovy and Mounjaro. The phrase FDA cited did not appear on the homepage at that check, though we did not review the whole site.

Every other letter in this collection is about how a product was described. This one is about how the pharmacy behind it was described, and it corrects a phrase that turns up constantly in this market. A compounder can register with FDA as an outsourcing facility under section 503B, and many advertise that they have. Registration is not approval and not a licence — FDA says in this letter that no such designation exists for these facilities, and that their compounded products get no premarket review at all. So a reassurance about the pharmacy is not a reassurance about the medicine, and it is not a credential a regulator issued. Set against a price, it is worth almost nothing: two sellers at very different prices can both truthfully say their compounder is FDA-registered, because the phrase does not describe the product either of them ships.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Eden failed to respond.